Sobre nós Contatos Interações: 118 620
Pesquisa de medicamentos por nome

Prevpac e Disfunção renal

Resultado da verificação da interação do medicamento Prevpac com doença Disfunção renal quanto a segurança no uso em conjunto.

Resultado da verificação:
Prevpac <> Disfunção renal
Relevância: 23.07.2019 Revisor: Shkutko P.M., M.D., in

Na verificação da interação, conforme informações das fontes confiáveis como Drugs.com, Rxlist.com, Webmd.com, Medscape.com, foram identificadas as contra-indicações ou efeitos colaterais que podem prejudicar a saúde ou aumentar efeito negativo ao consumir o medicamento com esta doença concomitante.

Consumidor:

A maioria dos antibióticos beta-lactâmicos são eliminados pelo rim como droga inalterada e, em alguns casos, também como metabólitos. As concentrações de soro de antibióticos beta-lactâmicos e seus metabólitos podem ser aumentados e a meia-vida prolongada em doentes com compromisso da função renal. Dosagem podem ser necessários ajustamentos e modificações devem ser com base no grau de insuficiência renal, bem como a severidade da infecção, de acordo com o produto individual rotulagem pacote. A função Renal testes devem ser realizados periodicamente durante o uso prolongado e/ou altas doses de terapia, pois a nefrotoxicidade e alterações da função renal tem sido ocasionalmente associado com o uso destas drogas.

Referências
  • DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992): s16-9
  • Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974): 36-52
  • Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985): 191-201
  • Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975): 443-8
  • "Product Information. Geocillin (carbenicillin)." Roerig Division, New York, NY.
  • Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993): 311-6
  • "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc, Baltimore, MD.
  • Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975): 692-700
  • Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986): 485-90
  • Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977): 299-308
  • Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978): 971-4
  • St Peter JV, Borin MT, Hughes GS, et al "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992): 126-31
  • Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994): 447-50
  • Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970): 349-56
  • Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977): 730-2
  • Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980): 155-6
  • Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997): 1022-33
  • Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981): 32-42
  • "Product Information. Spectrobid (bacampicillin)." Roerig Division, New York, NY.
  • Berman SJ, Boughton WH, Sugihara JG, et al "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978): 281-3
  • Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971): 69-77
  • Santoro J, Agarwal BN, Martinelli R, et al "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978): 951-4
  • Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978): 902
  • Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978): s88-99
  • Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970): 60-4
  • Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979): 189-95
  • Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979): 429-51
  • Arancibia A, Droguett MT, Fuentes G, et al "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982): 447-53
  • "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn, Kalamazoo, MI.
  • Chow M, Quintiliani R, Cunha BA, et al "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979): 185-94
  • Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972): 201-4
  • Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982): 39-46
  • "Product Information. Velosef (cephradine)." Apothecon Inc, Plainsboro, NJ.
  • "Product Information. Cedax (ceftibuten)." Schering-Plough, Liberty Corner, NJ.
  • Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979): 465-70
  • "Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb, Princeton, NJ.
  • Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970): 57-9
  • Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981): 110-6
  • Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990): 157-62
  • Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971): 540-3
  • "Product Information. Lorabid (loracarbef)." Lilly, Eli and Company, Indianapolis, IN.
  • Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971): 41-6
  • "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company, Indianapolis, IN.
  • Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978): s88-97
  • "Product Information. Omnicef (cefdinir)." Parke-Davis, Morris Plains, NJ.
  • Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970): 173-8
  • Spyker DA, Gober LL, Scheld WM, et al "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982): 278-81
  • Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972): 422-5
  • Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988): 83-94
  • Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997): 121-5
  • "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc, Deerfield, IL.
  • Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973): 486-7
  • "Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb, Princeton, NJ.
  • Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978): 172-7
  • "Product Information. Amoxil (amoxicillin)." SmithKline Beecham, Philadelphia, PA.
  • Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970): 57-9
  • Dhib M, Moulin B, Leroy A, et al "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991): 579-83
  • Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970): s9-13
  • Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979): 28-33
  • "Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.
  • Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990): 893-9
  • Hori R, Okumura K, Nihira H, et al "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985): 290-5
  • Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975): 666-73
  • Shyu WC, Pittman KA, Wilber RB, et al "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991): 362-71
  • "Product Information. Keflex (cephalexin)." Dista Products Company, Indianapolis, IN.
  • Pommer W, Krause PH, Berg PA, et al "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986): 290-3
  • Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970): 133-42
Prevpac

Nome genérico: amoxicillin / clarithromycin / lansoprazole

Marca comercial: Prevpac

Sinônimos: não

Prevpac <> Disfunção renal
Relevância: 23.07.2019 Revisor: Shkutko P.M., M.D., in

Na verificação da interação, conforme informações das fontes confiáveis como Drugs.com, Rxlist.com, Webmd.com, Medscape.com, foram identificadas as contra-indicações ou efeitos colaterais que podem prejudicar a saúde ou aumentar efeito negativo ao consumir o medicamento com esta doença concomitante.

Consumidor:

Claritromicina e a sua principal, metabólito ativo são dois eliminados pelo rim, em certa medida. A dose diária deve ser reduzida pela metade em pacientes com insuficiência renal grave (CrCl < 30 mL/min). Ajustes de dose não são geralmente necessária em pacientes com da leve a moderada, insuficiência renal, apesar de, teoricamente, interações acumulação pode ocorrer nesses pacientes, se eles têm concomitante de doença hepática.

Referências
  • Hardy D, Guay D, Jones R "Clarithromycin, a unique macrolide." Diagn Microbiol Infect Dis 15 (1992): 39-53
  • Zuckerman JM, Kaye KM "The newer macrolides: azithromycin and clarithromycin." Infect Dis Clin North Am 9 (1995): 731-45
  • Peters D, Clissold S "Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential." Drugs 44 (1992): 117-64
  • Davey PG "The pharmacokinetics of clarithromycin and its 14-OH metabolite." J Hosp Infect 19 (1991): 29-37
  • Ferrero JL, Bopp BA, Marsh KC, et al "Metabolism and disposition of clarithromycin in man." Drug Metab Dispos 18 (1990): 441-6
  • "Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical, Abbott Park, IL.
  • Chu S, Wilson DS, Deaton RL, Mackenthun AV, Eason CN, Cavanaugh JH "Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial." J Clin Pharmacol 33 (1993): 719-26
Prevpac

Nome genérico: amoxicillin / clarithromycin / lansoprazole

Marca comercial: Prevpac

Sinônimos: não

Interação entre medicamento, comida e estilo de vida
Interações medicamentosas